cro.directory
← Compare landing

Genevoyager (Wuhan) Co., Ltd. vs uBriGene

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/genevoyager-2/ubrigene

CategoryGenevoyager (Wuhan) Co., Ltd.uBriGene
Listed sitebothboth
SummaryLeading CRO/CDMO provider specializing in viral vectors, proteins, and vaccines with proprietary AAV manufacturing technology and cGMP-grade facilities operational since October 2023.uBriGene is a global leader in advanced therapy medicinal products (ATMPs), cell and gene therapy CDMO services, and analytical testing.
Services
  • Translational Research
  • Analytical Method Development & Validation
  • Regulatory Affairs
  • Analytical Method Development & Validation
  • US FDA Regulatory Strategy
  • EU EMA Regulatory Strategy
  • China NMPA Regulatory Strategy
  • Translational Research
Modalities
  • Biologics (Other)
  • Vaccine
  • AAV / Viral Vector Platform
  • mRNA
  • Cell Therapy
  • Gene Therapy
  • AAV / Viral Vector Platform
IndicationsData not yet provided.
  • Oncology
Locations
  • Headquarters & cGMP Facility, Wuhan, Jiangxia District, China
  • Headquarters, Maryland, Maryland, USA
  • Boston, Boston, Massachusetts, USA
  • Worcester, Worcester, Massachusetts, USA
Certifications
  • China · Identifier: High-tech Enterprise (高新技术企业)
  • FDA · Identifier: 20+ INDs filed and accepted
  • EMA · Identifier: 20+ INDs filed and accepted
  • NMPA · Identifier: 20+ INDs filed and accepted
ReviewsReview summary appears after site-level review signal gate opens.Review summary appears after site-level review signal gate opens.